Screening In-Depth Focus 2017
In this In-Depth Focus on Screening, we look at clinically-oriented phenotypic screening and explore how 3-D bioprinted tissues can be used as disease-in-a-dish models for drug screening.
List view / Grid view
Articles
Informatics In-Depth Focus 2017
In this In-Depth Focus we look at using bioinformatics sequence similarities to optimise repurposing activities; informatics infrastructure in neglected disease research, and machine learning for accelerating drug discovery.
3-D bioprinted tissues as disease-in-a-dish models for drug screening
More than 90% of drugs that enter clinical evaluation fail to reach approval because of lack of efficacy or unexpected toxicity. This failure rate is in large part due to the use of overly simplistic in-vitro cell-based assays and animal models with limited predictive value...
Hit To Lead In-Depth Focus 2017
In this In-Depth Focus we look at a pragmatic approach to hit validation following biochemical high-throughput screening as well as identification of hits and leads for human African trypanosomiasis.
Clinically-oriented phenotypic screening: understanding and exploiting the dynamic nature of the cancer cell phenotype
Understanding the cancer cell phenotype is central to both cancer diagnosis and treatment. Discrete molecular signatures among cancer phenotypes underpin patient stratification, while rapid methods for detailed phenotyping in the clinic (via liquid biopsies and tumour imaging) enable the delivery of personalised, effective precision medicines to the cancer patient...
Drug Target Review – Issue #4 2017
Issue 4 of Drug Target Review looks at artificial intelligence in drug discovery and features In-Depth Focuses on Screening, Hit to Lead and Informatics.
Drug patents expire. Can IP data help you prepare?
When important and valuable patents expire, some rejoice and some dismay. Usually, after 20 years of protection, a masterpiece becomes available to all to reproduce, at the loss of the former patent owner...
Flow cytometry – accelerating neuroscience research
Flow cytometry continues to evolve at a fast pace and provides neuroscientists with the ability to perform many highly-specialised assays simultaneously. It meets the demands of cutting-edge research in neuroscience that has allowed researchers to isolate particular neural cells from heterogeneous population and catalogue its molecular or physical features...
Assay development for image-based high-content screening
Image-based high-content screening (HCS) is a high-throughput screening (HTS) technology that combines automated fluorescence microscopy from microtiter plates with digital image analysis. This effectively allows phenotypic screening with sufficient throughput to interrogate large compound libraries...
Structure based drug discovery facilitated by crystallography
Drugs exert therapeutically meaningful effects if they bind with appropriate selectively and potency to their respective targets. Although many of the assay techniques employed in early-stage drug discovery provide evidence that a drug is acting upon the target under investigation, this is often indirect and the site of action and…
Expert view: Innovations in 3D
Physiologically relevant models to evaluate the effects of drug candidates early in the drug discovery and development process are becoming increasingly important to develop. Various 3D cell/tissue models have emerged offering relevant environment for ex vivo assays, but significant progress is required to streamline and automate the end-to-end workflow. Several…
EUTCD-Grade lines: an innovative approach to creating and supplying clinical hESC lines
The ever-increasing pressure to turn bench-top discoveries into new therapies has led to the re-purposing of embryonic stem cell lines, originally intended for basic research, for clinical applications...
Expert view: A technological breakthrough in flow cytometry
Flow cytometry has become a widely used technology in life science research. It is also essential for many pharma and biotechnology companies due to its proficiency in identifying biomarkers, developing biopharmaceuticals, and assessing the efficiency of new pharmacological protocols...
Expert view: Advances in NGS technology
The multiplex and high-throughput capabilities of next-generation sequencing (NGS) allow researchers to study an immense number of DNA/RNA molecules per run, bringing opportunities to study biological or clinical research questions that could not be addressed before...
How next-generation sequencing is opening the door for drug discovery
The Wellcome Trust Sanger Institute's Kim Judge explains how Next Generation Sequencing forms a crucial part of the scientist’s toolkit and makes a valuable contribution to the field of drug discovery...
